Shannon Connelly


Novel Frontline Regimen Improves PFS in Older Patients With MCL

February 21st 2019

The 4-drug combination of rituximab, bendamustine, bortezomib, and dexamethasone was found to improve progression-free survival and demonstrated a tolerable safety profile as frontline treatment for patients with mantle cell lymphoma who are ≥65 years.

PFS Benefit Confirmed With Daratumumab Plus VMP in Newly Diagnosed Myeloma

January 22nd 2019

Maria-Victoria Mateos, MD, PhD, discusses the updated findings from the ALCYONE trial in patients with newly diagnosed multiple myeloma.

BTK Inhibition Continues to Show Promise in Relapsed/Refractory MCL

January 15th 2019

Krish Patel, MD, discusses some of the most significant mantle cell lymphoma data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.

Expert Highlights Assay to Determine Patients With Lung, Gastrointestinal Cancers to Receive Pembrolizumab

August 10th 2018

The PD-L1 immunohistochemistry 22C3 pharmDx can be an aid in identifying patients with non–small cell lung cancer and gastrointestinal cancers who are eligible for pembrolizumab (Keytruda) monotherapy.

Marshall Highlights Durable Benefits of Pembrolizumab in GI Cancers

May 3rd 2018

Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.

Naidoo Discusses Advances in the Management of Immunotherapy-Related AEs

March 13th 2018

Jarushka Naidoo, MBBCh, discusses some of the most commonly seen immune-related adverse events in patients with lung cancer and how to manage them.

Wakelee Discusses Debate Surrounding Osimertinib in Frontline EGFR-Mutant Lung Cancer

March 11th 2018

Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.

Findings Support Nab-Paclitaxel as Top Choice for First-Line TNBC Therapy

February 16th 2018

Hope S. Rugo, MD, discusses the importance of individualizing doses of nab-paclitaxel in triple-negative breast cancer.

Progression Issues Surface With NSCLC Immunotherapy

October 27th 2017

Paul A. Bunn Jr, MD, discusses strategies for analyzing and responding to signs of progression for patients receiving immunotherapy for non-small cell lung cancer.

Expert Discusses De-Escalation Difficulties, Other Topics in TNBC

August 13th 2017

Lisa Carey, MD, discusses the challenges with de-escalation in patients with TNBC and steps toward overcoming these obstacles.

Treatment Considerations in Older Patients With Breast Cancer

August 10th 2017

Arti Hurria, MD, discusses the unique challenges with treating elderly patients with breast cancer and the exciting opportunities she envisions for advancing care in this setting.

Pegram Discusses Latest Developments in HER2+ Breast Cancer

August 9th 2017

Mark Pegram, MD, discusses emerging treatments in HER2-positive breast cancer and his vision for the future of the field.

Weber Says Pembrolizumab/Epacadostat Could Become Frontline Treatment of Choice in Melanoma

June 30th 2017

Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).

Expert Discusses Durvalumab for Urothelial Carcinoma

June 20th 2017

Christophe Massard, MD, PhD, discusses the latest developments with durvalumab (Imfinzi) in urothelial carcinoma.

Lead Researcher Discusses Midostaurin in AML

May 5th 2017

Richard M. Stone, MD, discusses the impact that midostaurin could have for patients with AML, as well as ongoing research with the agent.

Health Policy Director Discusses ACCC's Take on ACA Repeal, MedPAC's Part B Recommendations

April 28th 2017

Leah Ralph discusses the ACCC’s position on the Afforadable Care Act repeal bill, the Medicare Payment Advisory Commission’s Part B cost control proposals, and the possibility for comprehensive reform on the 340B Drug Discount Program.

Expert Addresses Issues in Advanced Gynecologic Cancers

April 26th 2017

Dana Chase, MD, discusses obstacles to progress and her hope for the future in advanced gynecologic cancers.

Expert Highlights Rapidly Evolving Biomarker Development in Prostate Cancer

April 24th 2017

Leonard Gomella, MD, discusses the future of biomarkers in prostate cancer.

Inherited Mutations Play Greater Role in CRC Than Previously Thought

April 20th 2017

Matthew B. Yurgelun, MD, discusses a study that determined that nearly 10% of patients with colorectal cancer had germline cancer susceptibility gene mutations and its implications for patients and their families.

Brahmer Highlights 5-Year Nivolumab Findings in NSCLC

April 18th 2017

Julie R. Brahmer, MD, discusses the 5-year findings of nivolumab in non-small cell lung cancer, their significance, and expected next steps for this research.